Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study

ObjectiveImmune checkpoint inhibitors (ICIs) have recently been increasingly used in cancer treatment, whereas their clinical application in biliary tract cancer (BTC) patients is uncommon. This study aimed to evaluate the efficacy and safety of ICIs plus capecitabine and oxaliplatin (CAPOX) in the...

Full description

Bibliographic Details
Main Authors: Jie Zhao, Yongzhong Guo, Wenzhou Ding, Guoyong Han, Chuanwei Jiang, Chao Yang, Yuanchang Hu, Long Zhang, Chen Wu, Ming Ni, Xiangyi Kong, Tian Huang, Chuanyong Zhang, Yongxiang Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitors
CAPOX
biliary tract cancer
efficacy
safety
prognostic factors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.965711/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.965711/full

Similar Items